NASDAQ: STAA · Medical Instruments & Supplies
STAAR Surgical (STAA) fair value: undervalued or overvalued?
As of 14 Nov 2026, Faircurve's model values STAAR Surgical (STAA) at $24.60 a share. The stock last closed at $26.01, which puts the model's fair value 5.4% below the price. On the model's bands that reads as Fairly valued.
Revalued . Price is the close of 16 Nov 2026. STAAR Surgical Company.
The report adds the live price, the chart against the range the options market prices, the next earnings date and the analysts' consensus. No account needed.
This week, in three parts
What happenedThe run of 14 Nov 2026 moved the fair value from $23.51 to $24.60 (+4.6%). Analysts raised their next-twelve-month EBITDA estimates: most of the move.
What the model makes of itThe price of $26.01 is 5.4% above it: Fairly valued, on a medium evidence grade.
What's nextNext report on 2 Mar 2027. Options prices imply a move of about 17% either way over the next month. The next weekly run is on Saturday 21 Nov 2026.
What price range does the model give STAA?
The calibrated range for STAA over 63 trading days is $21.40 to $31.92. It sits around the last close, and its width comes from the volatility that STAA's own options imply (59% a year), calibrated weekly against realised prices (n = 8,038 past valuations, refreshed 14 Nov 2026). Ranges built this way held the price 60% of the time at this horizon. The fair value is the model's opinion and rides beside the range. It is not the centre of it.
The model's own simulated range, from the 20th to the 80th percentile of its runs, is $20.24 to $29.95. In 38% of the simulations the fair value came out above the price the model ran on.
Faircurve Insights · 14 Nov 2026
STAAR Surgical Company, along with its subsidiaries, specialises in ophthalmological solutions. It designs, develops, manufactures and commercialises implantable lenses for vision correction, complete with the sophisticated delivery.
The model's fair value for STAAR Surgical is $24.60 a share, as of 14 Nov 2026. This is the midpoint of 2,000 simulations. The previous run, on 7 Nov 2026, gave $23.51, so the fair value moved +4.6%. In the model's own words, analysts raised their next-twelve-month EBITDA estimates: most of the move. The calibrated range over 63 trading days is $19.67 to $29.22. It is built from the fair value, since there is no live options data for the stock. Ranges built this way held the price 60% of the time at this horizon. The evidence grade is Medium. It looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It does not say whether the fair value is right.
The business scores 62 out of 100 on the model's overall quality score, a composite of six factors measured against comparable companies. Three factors stand out. Balance sheet scores 100, with net debt to EBITDA at -5.87x against a peer median of 2.54x. Stability scores 0, with five-year EBITDA margin downside volatility at 15.1 pts against a peer median of 1.6 pts. Growth quality scores 55, with trailing revenue growth at -23.7% against a peer median of 9.7%. The model compares the company with LeMaitre Vascular, DENTSPLY SIRONA, ICU Medical, Merit Medical Systems, Teleflex and AptarGroup.
Written from the figures on this page for the 14 Nov 2026 valuation and checked by rule before publishing: every number is one printed here, no forecast, no instruction. The price, the gap and the verdict are the page's own and change daily. Not a recommendation.
The Global Pulse
Faircurve's note after each US session, in your inbox. No account needed.
When does STAA report earnings, and how has the stock reacted?
STAAR Surgical's next earnings report is scheduled for 2 Mar 2027. Companies can move their dates.
Options prices on 16 Nov 2026 imply a move of about 13.7% in either direction through the nearest expiry, about 31 days out. That is the size the market is pricing, not a direction. STAA's 30 day implied volatility works out to about 17.1% over one month.
On 11 Nov 2026 STAA moved 11.8% in one session, against the 3.0% a day that options had priced: 3.9 times the implied size.
Around its last 8 reports: what the options market priced, and what followed
Each move runs from the last close before the report to the first close after it, so it covers companies that report before the open and after the close. The median size across STAA's last 8 reports, ignoring direction, was 4.8%.
What the options market has priced for a month's move in STAA
How does STAA score on business quality?
STAAR Surgical's overall quality score is 62 out of 100. Each factor below is a score against comparable companies, not a percentile of the metric beside it.
| Factor | Score (0 to 100) | Headline measure | Peer median |
|---|---|---|---|
| ProfitabilityReturn on invested capital against the peer group, with a bonus for an improving trend. | 50 | 5.2%ROIC | 3.2% |
| Earnings qualityHow much of reported profit is cash: free cash flow to net income, and the accrual ratio (the share of earnings that is not cash). | 89 | 33.67xFCF / net income | |
| Growth qualityTrailing revenue growth, forward growth from consensus, and the direction of analysts' rating changes. | 55 | -23.7%Revenue growth, trailing | 9.7% |
| Capital disciplineReinvestment efficiency (capital spending per unit of revenue) and net buybacks. | 83 | 0.5%Net buybacks / market value | 0.1% |
| Balance sheetNet debt to EBITDA and interest coverage. | 100 | -5.87xNet debt / EBITDA | 2.54x |
| StabilityDownside volatility of the EBITDA margin over the last five years. | 0 | 15.1 ptsEBITDA margin downside volatility, 5y | 1.6 pts |
How does STAA compare with similar companies?
The companies in medical instruments & supplies closest to STAAR Surgical in market value, each on the same model and the same date.
| Company | Last close | Model fair value | Gap | Model verdict |
|---|---|---|---|---|
| LMAT LeMaitre Vascular, Inc. | $77.01 | $93.66 | +21.6% | Undervalued |
| XRAY DENTSPLY SIRONA Inc. | $8.95 | $13.35 | +49.2% | Undervalued |
| NVST Envista Holdings Corp | $24.03 | $25.54 | +6.3% | Low evidence grade |
| ICUI ICU Medical, Inc. | $181.87 | $202.62 | +11.4% | Fairly valued |
| EMBC Embecta Corp. | $6.25 | $7.68 | +22.9% | Low evidence grade |
| MMSI Merit Medical Systems, Inc. | $86.35 | $82.63 | -4.3% | Fairly valued |
| TFX Teleflex Incorporated | $157.10 | $169.00 | +7.6% | Fairly valued |
| ATR AptarGroup, Inc. | $143.17 | $137.10 | -4.2% | Fairly valued |
What the comparable companies' multiples alone would give for STAA, the peer-implied price, is $11.59 a share on this run. The fair value weighs that against the company's own multiple.
All medical instruments & supplies stocks ranked by gap to fair value
STAAR Surgical at a glance
STAAR Surgical Company, along with its subsidiaries, specializes in ophthalmological solutions, focusing on the design, development, manufacturing, and commercialization of implantable lenses for vision correction, complete with the sophisticated delivery.
- Market value
- $1.3B
- Sector
- Healthcare
- Industry
- Medical Instruments & Supplies
- Revenue expected, next twelve months
- $366M
- Consensus revenue growth, next fiscal year
- +41.9%
- Analysts with estimates
- 5
- Beta to the US market
- 0.30
- First valued by Faircurve
- 11 Jul 2026
At the close of 16 Nov 2026, 56.8% of the 1,085 graded US stocks the model covers traded below the model's fair value. STAA was not among them.
How the fair value is worked out: the model prices STAAR Surgical on the value of the whole business, debt included, against the operating profit analysts expect next year (forward EV/EBITDA), runs 2,000 simulations across its inputs and takes the midpoint. The full method is documented here.
What changed in the latest valuation?
On 7 Nov 2026 the model's fair value for STAA was $23.51. As of 14 Nov 2026 it is $24.60, a change of +4.6%. Analysts raised their next-twelve-month EBITDA estimates: most of the move. The model revalues every stock it covers each week, and again after an earnings report.
Questions about STAAR Surgical's valuation
Is STAAR Surgical stock undervalued or overvalued?
On Faircurve's model, STAA reads as Fairly valued as of 14 Nov 2026. The model's fair value is $24.60 a share against a last close of $26.01, a gap of -5.4%.
What is STAA's fair value?
$24.60 a share as of 14 Nov 2026, the midpoint of 2,000 simulations. The model's own 20th to 80th percentile range is $20.24 to $29.95.
What price range does the model give STAA?
$21.40 to $31.92 over 63 trading days. Ranges built this way held the price 60% of the time across 8,038 past valuations, refreshed 14 Nov 2026.
When does STAAR Surgical report earnings next?
The next report is scheduled for 2 Mar 2027. Companies can move their dates.
How much has STAA moved on past earnings reports?
Across its last 8 reports the median two session move was 4.8%, ignoring direction. The largest was -27.1% around the report of 11 Feb 2025.
How confident is the model in this valuation?
The model's evidence grade for STAA is medium. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It is not a probability that the fair value is right, or that the price reaches it.
The model's own ideas on STAA
The model holds no idea open on STAA today. Signed-in readers see the rule each idea runs on, the floor and the exit level the model set and its time limit, and the model's closed ideas on STAA with their outcomes. A free account is enough.